The pain field has seen its share of disappointment on the drug development front, to the point where the so-called “failure of translation” has become an unavoidable cliché. But over the past several months, the migraine field’s own search for new medications has turned out quite differently, with several innovative medications receiving regulatory approval. Those who treat migraine and people who suffer from it can now celebrate another triumph.
Published by Pain Research Forum.
